PROTAGENIC THERAPEUTICS INC C/WTS 26/04/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -2.75

EPS: As of FY2025 Q1, the actual value is USD -2.75.

EBIT: As of FY2025 Q1, the actual value is USD -1.44 M.

Segment Revenue

Protagenic Therapeutics, Inc. did not generate any revenue during the three months ended March 31, 2025, as the company is still in the development stage and focused on clinical trials for FDA approval and commercialization of its product.

Operational Metrics

• Net Loss: The company reported a net loss of - $1,440,005 for the three months ended March 31, 2025, compared to a net loss of - $1,724,294 for the same period in 2024.
• Research and Development Expenses: R&D expenses decreased to $880,372 in 2025 from $1,460,746 in 2024, primarily due to lower expenses related to clinical trials and changes in research partners.
• General and Administrative Expenses: These expenses increased to $567,736 in 2025 from $277,613 in 2024, driven by higher stock compensation and legal expenses.

Cash Flow

• Operating Cash Flow: The net cash used in operating activities was - $1,068,017 for the three months ended March 31, 2025, compared to - $1,659,185 for the same period in 2024.
• Investing Cash Flow: There was no cash provided by investing activities in 2025, compared to $1,202,880 in 2024.
• Financing Cash Flow: The company raised $102,519 from the sale of common stock during the three months ended March 31, 2025.

Future Outlook and Strategy

• Core Business Focus: Protagenic Therapeutics, Inc. plans to continue its preclinical studies, clinical trials, and product development activities for its pipeline of product candidates, including PT00114, which is in Phase I/IIa clinical trials for treating neuro-psychiatric conditions.
• Liquidity Concerns: The company anticipates further losses and does not have sufficient resources to fund operations beyond twelve months from the date of the financial statements. It will need to obtain additional financing by the third quarter of 2025.